Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinoma
AssigneeProteosys AG
InventorAndre Schrattenholz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies.
Claims18
A method for the diagnosis of prostate or colon cancer comprising analyzing a sample for the presence and/or amount of annexin A3 by detecting annexin A3 with an antibody specific for annexin A3 which has essentially no crossreactivity against other annexins, wherein the antibody is selected from an antibody produced by the hybridoma cell lines tgc 5 ProII6G7(DSM ACC2778), tgc 6 ProIII1G11(DSM ACC2779), tgc 7 ProVII5C5(DSM ACC2780), tgc 8 ProIII1E1(DSM ACC2781), tgc 13 ProI/5G9, tgc 12 ProIII/4B11, tgc 14 ProVIII/3D7, or an antibody which binds to the same epitopes on annexin A3 as bound by the antibodies produced by said hybridoma cell lines.
Dependencies are inferred from the claim text.